Serious adverse events: intussusception · children
RotaTeq showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
3 findings from 1 review
RR 0.69 [0.35, 1.38]
9 studies · 73925 participants
Low
RR 5.01 [0.24, 104.29]
2 studies · 4082 participants
Very low
RR 0.33 [0.01, 8.16]
2 studies · 7488 participants
Low
Serious adverse events: intussusception · children
Rotasiil showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: intussusception · children
It is very uncertain whether rotavac changes serious adverse events: intussusception compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in study withdrawals due to adverse events compared with skim milk, plus lactose powder (low certainty).
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Adverse events: psychological disorders · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: psychological disorders compared with three months (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: psychological disorders compared with 2 months of therapy (low certainty).
1 finding from 1 review
adverse events: grade 1 to 2 dermatitis · healthy men
Selenium leads to higher adverse events: grade 1 to 2 dermatitis compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Serious adverse events: hospitalisation · adults with CVD
1 finding from 1 review
Adverse events in the mother ‐ Bleeding · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin showed no clear difference in adverse events in the mother ‐ Bleeding compared with aspirin (low certainty).
1 finding from 1 review
Adverse events in the mother ‐ Bleeding · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes adverse events in the mother ‐ Bleeding compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Intra‐operative bleeding · participants with β‐thalassaemia
It is very uncertain whether the intervention changes adverse events Intra‐operative bleeding (very low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
YinDanXingNaoTong showed no clear difference in adverse events (AEs) (1 or more events) compared with 'no treatment' (low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
It is very uncertain whether naoMaiTai changes adverse events (AEs) (1 or more events) compared with western medicine (very low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
NaoXinTong showed no clear difference in adverse events (AEs) (1 or more events) compared with western medicine (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
ShenFuTang showed no clear difference in adverse events (AEs) (1 or more events) compared with western medicine (low certainty).
1 finding from 1 review